Artiva Biotherapeutics, Inc.

ARTV

Artiva Biotherapeutics, Inc.

ARTV

Insider Sentiment (TTM):

Last Purchase:2026-06-26Last Sale:2026-05-19Shares Purchased (TTM):8,270,834Shares Sold (TTM):113,602

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:16,834,243Shares Outstanding:49,356,840Institutional Ownership Pct.:34.11%

Earnings Market Reaction:

Filing Date:2026-05-08Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Biological Products, (No Diagnostic Substances)

AMGN GILD SCLX BIIB MRNA RVMD

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	21	27	26	28	30	40	56	34
Short Term Investments	66	81	97	114	136	145	91	12
Accounts Receivable Net Current	-	-	-	-	-	0	1	1
Other Receivables Net Current	-	0	0	0	0	0	0	1
Prepaid Expense And Other Assets Current	2	5	6	7	4	3	3	2
Assets Current	89	113	130	149	170	189	151	50
Restricted Cash Noncurrent	0	0	0	0	0	0	0	0
Property Plant And Equipment Net	6	7	7	7	7	6	7	7
Operating Lease Right Of Use Asset	10	11	11	13	13	14	14	15
Finance Lease Right Of Use Asset	0	0	0	0	0	0	0	0
Deferred Costs	-	-	-	-	-	-	-	3
Long Term Investments	-	-	-	-	-	-	53	-
Other Assets Noncurrent	0	0	0	0	0	0	0	0
Assets	106	131	149	169	191	210	226	76
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	2	0	1	1	2	1	1	1
Accrued Liabilities Current	6	10	7	6	6	7	8	6
Operating Lease Liability Current	3	3	3	4	4	4	4	4
Finance Lease Liability Current	0	0	0	0	0	0	0	0
Other Liabilities Current	-	0	0	0	0	-	-	-
Liabilities Current	11	13	11	11	12	12	13	11
Operating Lease Liability Noncurrent	7	8	9	10	10	11	11	12
Finance Lease Liability Noncurrent	-	-	-	-	0	0	0	0
Derivative Liabilities Noncurrent	-	-	-	-	-	-	-	28
Other Liabilities Noncurrent	-	-	-	-	-	0	0	0
Liabilities	18	21	20	20	22	23	25	51
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	-
Additional Paid In Capital Common Stock	442	440	439	437	436	433	431	22
Accumulated Other Comprehensive Income Loss Net Of…	-0	0	0	0	-	-0	0	0
Retained Earnings Accumulated Deficit	-354	-331	-310	-288	-267	-247	-231	-213
Stockholders Equity	88	110	129	149	169	187	201	-191
Liabilities And Stockholders Equity	106	131	149	169	191	210	226	76
Temporary Equity Par Or Stated Value Per Share	-	-	-	-	-	-	-	0
Preferred Stock Shares Authorized	-	-	-	-	-	-	-	10
Common Stock Par Or Stated Value Per Share	-	-	-	-	-	-	-	0
Common Stock Shares Authorized	-	-	-	-	-	-	-	700
Common Stock Shares Issued	0	0	0	0	0	0	0	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-27.18%	-11.66%	-	-	-	-	-	-	-	-	-	-
2025	-11.47%	-32.57%	65.14%	9.76%	3.14%	88.50%	-15.58%	6.28%	-2.26%	10.86%	77.63%	30.43%
2024	-	-	-	10.27%	7.70%	-10.97%	-9.72%	-18.36%	-61.13%	-42.71%	-48.08%	-49.36%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Liquidity Ratios
Current Ratio	8.16	8.61	11.65	13.84	13.93	15.39	11.33	4.59
Quick Ratio	7.98	8.26	11.07	13.22	13.62	15.15	11.08	4.43
Working Capital	77.86M	99.58M	118.41M	138.30M	157.80M	176.38M	137.27M	38.92M
Leverage & Debt
Debt to Equity	0.21	0.19	0.15	0.14	0.13	0.12	0.12	-0.26
Debt Ratio	0.17	0.16	0.13	0.12	0.12	0.11	0.11	0.67
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	-	-	-
Per Share Metrics
Diluted EPS TTM	-1.76	-1.72	-1.90	-1.83	-1.76	-	-	-
Free Cash Flow Per Share TTM	-1.62	-1.62	-1.61	-1.45	-1.56	-	-	-
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	-	-	-
Margin Metrics
Operating Profit Margin TTM	-	-	-	-38,276.10%	-17,819.32%	-	-	-
Net Profit Margin TTM	-	-	-	-35,496.02%	-17,068.53%	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	-100.00%	-	-	-	-	-	-	-
Net Income Growth (1Y)	1.62%	-	-	-	-	-	-	-
EPS Growth (1Y)	0.23%	-	-	-	-	-	-	-
Valuation Metrics
P/E TTM	-3.65	-2.50	-1.51	-0.83	-1.70	-	-	-
P/B TTM	3.62	1.91	1.09	0.49	0.87	2.43	2.91	-
P/S TTM	-	-	-	293.32	290.94	-	-	-
Market Cap	317.86M	209.73M	140.53M	73.62M	146.05M	453.96M	583.91M	-
Enterprise Value	296.45M	182.61M	114.63M	44.80M	115.33M	413.89M	527.97M	-
Calculated Values
Free Cash Flow TTM	-80.18M	-79.34M	-78.91M	-70.81M	-76.03M	-	-	-
Net Debt	-21.41M	-27.12M	-25.89M	-28.82M	-30.73M	-40.07M	-55.95M	-34.28M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-26Purchase

Owner: Ra, Capital Management, L…

Title: -

Shares: 1,876

Price/Share: $8.98

Value: $16,846.48

Shares Owned: 16,795,919

Relationship: Director,TenPercentOwner

Ownership: Indirect

2026-06-16Purchase

Owner: Kolchinsky, Peter, Ra Cap…

Title: -

Shares: 124,893

Price/Share: $8.89

Value: $1,110,298.77

Shares Owned: 16,763,043

Relationship: Director,TenPercentOwner

Ownership: Indirect

2026-06-11Purchase

Owner: Ra, Capital Nexus Fund, L…

Title: -

Shares: 548,580

Price/Share: $7.91

Value: $4,339,267.80

Shares Owned: 16,231,717

Relationship: Director,TenPercentOwner

Ownership: Indirect

2026-05-19Sale

Owner: Aslan, Fred

Title: Chief Executive Officer

Shares: 27,116

Price/Share: $9.01

Value: $244,315.16

Shares Owned: 1,535,082

Relationship: Director,Officer

Ownership: Direct

2026-05-19Sale

Owner: Horan, Christopher

Title: Chief Tech Operations Officer

Shares: 7,002

Price/Share: $9.01

Value: $63,088.02

Shares Owned: 293,450

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-26	Ra, Capital Management, L…	Director,TenPercentOwner	-	Indirect	Purchase	1,876	8.98	$16,846.48	16,795,919	4
2026-06-16	Kolchinsky, Peter, Ra Cap…	Director,TenPercentOwner	-	Indirect	Purchase	124,893	8.89	$1,110,298.77	16,763,043	4
2026-06-11	Ra, Capital Nexus Fund, L…	Director,TenPercentOwner	-	Indirect	Purchase	548,580	7.91	$4,339,267.80	16,231,717	4
2026-05-19	Aslan, Fred	Director,Officer	Chief Executive Officer	Direct	Sale	27,116	9.01	$244,315.16	1,535,082	4
2026-05-19	Horan, Christopher	Officer	Chief Tech Operations Officer	Direct	Sale	7,002	9.01	$63,088.02	293,450	4
2026-05-19	Bush, Jennifer	Officer	COO, CLO, Compliance Officer	Direct	Sale	8,790	9.01	$79,197.90	337,920	4
2026-05-19	Banerjee, Subhashis	Officer	Chief Medical Officer	Direct	Sale	7,037	9.01	$63,403.37	144,963	4
2026-05-19	Raymon, Heather	Officer	SVP, Research and Development	Direct	Sale	3,095	9.01	$27,885.95	148,228	4
2026-05-11	Ra, Capital Nexus Fund Ii…	Director,TenPercentOwner	-	Indirect	Purchase	6,510,416	11.52	$74,999,992.32	15,203,995	4
2026-05-11	Gc, Corp., Gc Cell Corp	TenPercentOwner	-	Direct	Purchase	1,085,069	11.52	$12,499,994.88	4,391,969	4
2025-12-15	Aslan, Fred	Director,Officer	President and CEO	Direct	Sale	3,187	6.00	$19,122.00	1,209,948	4
2025-11-17	Aslan, Fred	Director,Officer	President and CEO	Direct	Sale	6,375	3.38	$21,547.50	343,999	4
2025-10-17	Aslan, Fred	Director,Officer	President and CEO	Direct	Sale	25,500	6.00	$153,000.00	356,721	4
2025-08-15	Aslan, Fred	Director,Officer	President and CEO	Direct	Sale	25,500	2.73	$69,615.00	386,693	4
2024-07-22	Kolchinsky, Peter, Shah R…	Director,TenPercentOwner	-	Indirect	Purchase	8,333,333	12.00	$99,999,996.00	8,693,579	4
2024-07-22	Gc, Cell Corp, Gc Corp.	TenPercentOwner	-	Direct	Purchase	1,666,666	12.00	$19,999,992.00	3,306,900	4
2024-07-22	Venbio, Global Strategic …	TenPercentOwner	-	Direct	Purchase	416,666	12.00	$4,999,992.00	1,936,637	4
2024-07-22	5Am, Partners Vi, Llc, 5A…	TenPercentOwner	-	Indirect	Purchase	833,333	12.00	$9,999,996.00	1,182,054	4
2024-07-22	Huh, Yong-Jun	Director	-	Indirect	Purchase	2,083,332	12.00	$24,999,984.00	3,306,900	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

34.11%

Inst. Shares: 16,834,243

Shares Outstanding: 49,356,840

2025-12-31

34.68%

Inst. Shares: 16,956,116

Shares Outstanding: 48,888,114

2025-09-30

37.02%

Inst. Shares: 18,125,838

Shares Outstanding: 48,963,444

2025-06-30

37.80%

Inst. Shares: 18,428,275

Shares Outstanding: 48,757,646

2025-03-31

42.86%

Inst. Shares: 20,864,108

Shares Outstanding: 48,683,956

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	16,834,243	49,356,840	34.11%
2025-12-31	16,956,116	48,888,114	34.68%
2025-09-30	18,125,838	48,963,444	37.02%
2025-06-30	18,428,275	48,757,646	37.80%
2025-03-31	20,864,108	48,683,956	42.86%
2024-12-31	21,133,841	45,035,404	46.93%
2024-09-30	20,676,697	37,793,658	54.71%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Artiva Biotherapeutics, Inc. (ARTV) — SEC Financial Statements & Analysis

Artiva Biotherapeutics, Inc. (ARTV) is a biological products, (no diagnostic substances) company, incorporated in DE. Artiva Biotherapeutics, Inc. trades on ARTV: Nasdaq as: ARTV. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Artiva Biotherapeutics, Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.21x, a Price-to-Sales (P/S) ratio of 293.32x (TTM), a Price-to-Book (P/B) ratio of 3.62 (TTM), at a market cap of $317.86M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.21x
P/S TTM: 293.32x
P/B TTM: 3.62
Market Cap: $317.86M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Artiva Biotherapeutics, Inc. in?

Artiva Biotherapeutics, Inc. (ARTV) operates in the Biological Products, (No Diagnostic Substances) industry.

What is ARTV's market cap?

Artiva Biotherapeutics, Inc. (ARTV) has a market capitalization of $317.86M as of 2026-03-31.

What exchange does ARTV trade on?

Artiva Biotherapeutics, Inc. (ARTV) trades on the ARTV: Nasdaq.

Where is Artiva Biotherapeutics, Inc. incorporated?

Artiva Biotherapeutics, Inc. is incorporated in DE.

Artiva Biotherapeutics, Inc. (ARTV) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.